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Background: The prognosis of patients with suspected pulmonary embolism (PE) in whom PE has been ruled out
(RPE) is unclear. We aimed to evaluate survival and diagnosis of new cancer in suspected PE patients at follow up.
Methods: A prospective cohort study nested in a prospective Institutional Registry of Venous Thromboembolic
Disease was performed between 2006 and 2011. This study was designed to evaluate all consecutive, incident cases
of suspected PE in adults. The study was performed at the Hospital Italiano de Buenos Aires, a tertiary level hospital,
in hospitalized patients and outpatients. Suspected PE cases were collected using a computerized system that alerts
whenever a physician requests pulmonary angiography, angiotomography, or ventilation-perfusion scintigraphy. PE
was defined by pre-specified criteria and RPE was defined when diagnostic tests were negative for PE.
Results: We included 1736 cases of suspected PE. The prevalence of PE was 29% (n = 504). There was no difference in
the overall survival at 30 days and follow-up between PE and RPE patients. The presence of provoked or unprovoked
venous thromboembolic disease in these patients did not affect survival. The main causes of death were PE in the
confirmed PE group (60%), and neoplasm (42%) and sepsis (37%) in the RPE group. Survival at 90 days was 63% for PE
(95% CI 58–67%) and 67% for RPE patients (95% CT 64–69%). At follow-up, there was no difference in diagnosis of new
cancer between PE and RPE patients (2% vs 2%, p = 0.82), even when taking into account the unprovoked group.
Conclusions: Even when the main cause of death in PE patients is PE itself, the overall mortality is similar between PE
and RPE patients. The reason for this finding could be because of the more frequent and severe comorbidities in RPE
than in PE patients.
Trial registration: HomeClinicalTrial.gov: NCT01372514
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Pulmonary embolism (PE) causes 5–10% of inpatient
deaths, representing the main cause of preventable deaths
in hospitalized patients [1]. Only 15–30% of suspected PE
cases are finally confirmed [2-12]. There are few reports
comparing the short-term and long-term mortality in pa-
tients with suspected PE, particularly for those in whom
PE has been ruled out (RPE) [13-18]. PE has a short-term
(30 days) and long-term mortality, which varies between* Correspondence: fernando.vazquez@hospitalitaliano.org.ar
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unless otherwise stated.5% and 30% [3,17,19-24]. Clinical manifestations of PE are
often nonspecific, and therefore, PE is challenging to diag-
nose. In fact, the risk factors for venous thrombosis dis-
ease (VTE) and comorbidities in confirmed PE and RPE
patients are similar [13], and may be determinant in the
prognosis of patients with suspected PE [13].
While the mortality of confirmed PE is not high when
the disease is promptly recognized and treated, PE may
have high mortality when it is massive or is not suspected
in the early stage. The prognostic information in patients
with confirmed PE versus those with RPE is limited. We
believe that all patients with suspected PE have a similar
prognosis because of the burden of comorbidity,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cations for providing information on the fragility of this
group of patients.
We performed a prospective cohort study to evaluate
the overall mortality in patients with suspected PE at a ter-
tiary level hospital. We compared short-term (30 days)
and long-term (2 years) mortality between confirmed PE
and RPE patients. Secondary objectives were to evaluate
the recurrence of VTE in confirmed PE, new VTE in RPE,
bleeding, and diagnosis of new cancer during follow-up.
Subanalysis was performed considering three groups ac-
cording to the presence or absence of risk factors for VTE
(cancer, and provoked and unprovoked VTE), which were
present in each patient at the time of the suspected PE.
Methods
We performed a prospective cohort study nested in the pro-
spective Institutional Registry of Venous Thromboembolic
Disease (IRTD Home ClinicalTrial.gov NCT01372514) be-
tween June 2006 and May 2011. This study was designed to
evaluate all consecutive incident cases of suspected PE at
the Hospital Italiano de Buenos Aires [25]. This hospital is a
tertiary level hospital with 675 beds, 42,700 admissions, and
almost 3 million ambulatory consultations each year.
Population
Suspected PE was considered if any patient (in the hospi-
talized or ambulatory setting) was assessed for PE with a
diagnostic test (computed tomography pulmonary angiog-
raphy [CTPA], ventilation-perfusion scintigraphy, or pul-
monary angiography).
The IRTD inclusion criteria were as follows: (1) all con-
secutive inpatients and outpatients older than 16 years of
age; (2) patients who were evaluated with a diagnostic test
(CTPA, ventilation-perfusion scintigraphy, or pulmonary
angiography) by the attending physician to confirm or rule
out PE because of the presence of signs and/or symptoms
suggestive of PE (defined as acute onset of new or worsen-
ing shortness of breath, tachycardia, or chest pain without
any other obvious etiology); and (3) confirmed deep vein
thrombosis (DVT) with an objective diagnostic test. Pa-
tients were excluded from the IRTD for the following rea-
sons: (1) patients were tested for any other reason than
suspected VTE; (2) patients were unable to provide in-
formed consent or refused to participate; and (3) patients
who only visited our hospital for a diagnostic study, but
were treated at other centers. For this study, we included
only those patients with suspicion of PE who were already
included in the IRTD.
Possible cases were collected for the IRTD using a com-
puterized alert that was generated whenever a physician
requested an imaging study for VTE among adult patients.
Data collection was carried out prospectively by medical
students who were specifically trained for this study. Theyinterviewed the patient and the treating physician using a
standardized data collection form. Baseline evaluation of
all patients, including the Wells score [26,27], was per-
formed during the first 24 hours since suspicion of PE,
without knowing the diagnostic test results.
PE was confirmed if CTPA or angiography showed fill-
ing defects in a sub-segmental or larger pulmonary artery,
and was present in at least two consecutive images, or
there was a high or intermediate probability of PE in
ventilation-perfusion scintigraphy, associated with a likely
Wells score probability [25,27]. All others cases were con-
sidered as RPE [27] and an alternative final diagnosis was
always confirmed.
In this study, patients were categorized according to
risk factors for VTE at the time of suspected PE for the
following: 1) active cancer (i.e., patients who were diag-
nosed with cancer or who had received cancer treatment
in the last 6 months); 2) provoked, which was defined as
patients with any risk factor for VTE (transient or not,
except for cancer) detected at the time of suspected PE
[28], including reduced mobility, advanced age (70 years
old or older), acute medical illness, recent major surgery
or trauma, spinal cord injury, obesity, hormone replace-
ment therapy, oral contraceptives, a cast or immobilizer,
pregnancy or postpartum period, recent travel (more
than 6 hours during the last 30 days), and thrombophi-
lia; and 3) unprovoked, which was defined as patients in
whom no evident risk factor for VTE was detected at
the time of suspected PE [29-31].
Follow-up was performed through medical electronic
records and structured phone call interviews, to assess
overall mortality and complications. All of the study pa-
tients were contacted every 6 months following the sus-
pected PE episode. The cause of death was determined
systematically by the treating physician and the principal
investigator.
Complications of VTE were considered as follows: 1)
major bleeding, which was defined by the International
Society of Thrombosis and Hemostasia [32]; 2) a new
VTE event (i.e., new symptomatic DVT and/or PE event
that was objectively confirmed; and 3) diagnosis of new
cancer (i.e., diagnosis of neoplasm 30 days after the sus-
pected PE event during follow-up).
This study was observational, and all diagnostic and
therapeutic medical decisions reflected current medical
practice. This study was approved by the ethics committee
of the Hospital Italiano de Buenos Aires (protocol # 995).
Informed consent was obtained from all participants.
Statistical analysis
Descriptive analysis for continuous variables is shown as
mean and standard deviation or median and interquar-
tile range, according to the observed distribution. Cat-
egorical variables are expressed as absolute number and
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were performed with the chi-square test for categorical
variables and the Mann–Whitney U test for continuous
variables.
For patients with SPE, survival was calculated with the
Kaplan–Meier estimator. Median survival time was
expressed with its 95% confidence interval (95% CI). Sur-
vival distribution according to VTE risk factor categories
(cancer, provoked, and unprovoked) was also estimated
with the Kaplan–Meier estimator. Survival curves were
compared between the PE and RPE groups with the
Mantel–Cox test.
Significance was defined as p < 0.05. All data analyses
were performed with IBM SPSS software, version 19
(SPSS, Chicago, IL).Results
Prevalence of PE
A total of 1736 patients were included for suspected PE in
the IRTD, and the prevalence of PE was 29% (n = 504)
(Figure 1). The prevalence of PE according to the main
risk factor was 29% (201/688) in the active cancer group,
29% (253/854) in the provoked group, and 26% (50/194)
in the unprovoked group.Alternative etiological diagnoses in RPE
The most common etiological diagnoses for RPE patients
were intrathoracic neoplasm (23%, 288/1232), congestive
heart failure (CHF) (21%, 256/1232), pneumonia (17%,
206/1232), chronic obstructive pulmonary disease (COPD)
(9%, 118/1232), sepsis (7%, 86/1232), acute coronary syn-
dromes, dissection or aneurysm of the aorta (3.5%, 43/
1232), and others (6%, 74/1232).Figure 1 Flow diagram of the study.Main characteristics of the patients
Patients with confirmed PE had a higher body mass index,
and a higher proportion of nephrotic syndrome and a his-
tory of VTE or major surgery within the last 30 days. RPE
patients had an increased frequency of CHF, coronary heart
disease, and heparin prophylaxis prior to the suspected PE
event (Tables 1 and 2). The simplified Wells score, which
was performed a priori to the diagnostic tests, accurately
discriminated between patients who finally had confirmed
PE and RPE (median, 4.5 points [95% CI 3–7] and 2.5 points
[95% CI 1–4], respectively, p < 0.01).
Survival of patients with PE and RPE during follow-up
The cumulative proportion surviving at 30 days for RPE
and confirmed PE was 0.76 (95% CI 0.73–0.78) vs 0.73
(95% CI 0.69–0.76), at 90 days it was 0.67 (95% CI 0.64–
0.69) vs 0.63 (95% CI 0.58–0.67), at 360 days it was 0.53
(95% CI 0.50–0.55) vs 0.49 (95% CI 0.44–0.54), and at
720 days it was 0.43 (95% CI 0.40–0.47) vs 0.43 (95% CI
0.38–0.47). There was no significant difference in the
distribution of survival between the groups (p = 0.52).
Figure 2 shows the Kaplan–Meier curve for PE and RPE
patients.
The overall median survival time was 421 days (95% CI
334–508). The median survival time was 438 days in RPE
patients (95% CI 343–533) and 351 days in confirmed PE
patients (95% CI 153–554). At 2 years of follow-up, 162
(9.3%) patients were lost to follow-up because of impossi-
bility of telephone contact. There was no significant differ-
ence in the number of patients who were lost to follow-up
between confirmed PE patients (52/504, 10%) and RPE pa-
tients (110/1232, 9%, p = 0.37, Table 3). Those who were
lost to follow-up were younger and healthier (less likely to
have cancer, immobilization and comorbidities) than those
who had complete follow-up.
Table 1 Baseline characteristics of the two groups
Confirmed PE Ruled out PE p
n = 504 n = 1232
Median age (IQR, interquartile range) years 71 (60–80) 71 (58–81) 0.36
Sex-Female, % (n) 58% (291) 60% (736) 0.45
Median stay (IQR) days 8 (5–15) 8 (4–14) 0.78
Comorbidities
Diabetes 12% (61) 15% (187) 0.09
Hypertension 63% (313) 67% (816) 0.09
Smoking 13% (64) 12% (144) 0.56
Heart Failure 10% (50) 20% (241)* 0.001
Coronary heart disease 10% (47) 14% (166)* 0.016
Dyslipidemia 48% (242) 45% (548) 0.2
Cerebrovascular Accident 5% (25) 6% (75) 0.47
Active neoplasia 40% (201) 40% (487) 0.89
Liver disease 1% (6) 1% (1) 0.50
Nephrotic syndrome 2% (7) 1% (4)* 0.012
Charlson Score* 2 (0–3) 2 (1–4)* 0.025
Immobilization within 4 weeks 64% (304) 64% (732) 0.98
Median Body Mass Index (IQR) kg/m2 29 (25–31) 28 (24–30)* 0.05
*p < 0.05. Categorical variables were compared with the chi2 test and continuous variables with the Mann Whitney U test.
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survival between PE and RPE patients, when adjusted for
the presence of the main risk factor for VTE (cancer, pro-
voked, and unprovoked, p = 0.73). Survival in cancer pa-
tients was worse than that in the other two groups.
Table 4 shows survival in PE and RPE patients stratified
by the main risk factor. The most frequent causes of death
at 90 days in patients who died after a confirmed PE event
were fatal PE (60%), sepsis (22%), and neoplasm (16%).Table 2 Risk factors by group
Confirmed P
n = 504% (n
Central venous catheter 10% (50)
Recent major surgery (<30 days) 30% (150)
Active cancer disease 40% (201)
Prior VTE event 16% (78)
Immobilization within 4 weeks 64% (304)
Pharmacological thromboprophylaxis$ 14% (70)
Recent trauma (<30 days) 8% (39)
Unprovoked 9.9% (50)
Medical reason for hospitalization 31% (55)
OC/HRT 2% (8)
Recent travel >6 hours 11% (54)
$The use of pharmacologic thromboprophylaxis was defined as the use of low mole
once daily) before being evaluated for suspected PE. *p < 0.05. Categorical variables
Whitney U test. Abbreviations: OC Oral contraceptives, HRT hormone replacement thThe most frequent causes of death in RPE patients were
neoplasm (42%) and sepsis (37%). Survival analysis based
on the main risk factor category at the time of suspected
PE (cancer, provoked, or unprovoked) failed to show any
significant difference (Table 4).
Complications at follow-up
PE patients had more recurrent VTE episodes compared
with RPE patients (11% vs 5%, p < 0.0001). Major bleedingE Ruled out PE p












cular weight heparin, unfractioned heparin (UFH) or fondaparinux (2.5 mg
were compared with the Chi2 test and continuous variables with the Mann
erapy.
Figure 2 Kaplan Meier survival curve of confirmed and ruled out PE during follow up.
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patients (7% vs 2%, p < 0.0001). The incidence of newly di-
agnosed malignancies was similar in PE and RPE patients
in the entire cohort (2% vs 2%, p = 0.82), and in the unpro-
voked subgroup in which only two new cancers were diag-
nosed in PE patients (p = 0.40).
Discussion
This study showed that patients with suspected PE had
high overall short-term and long-term mortality rates,
regardless of confirming or ruling out the diagnosis of
PE. Patients with confirmed PE in our study had similar
mortality rates to those reported in the literature
[19,23,33]. The similarity in mortality between PE pa-
tients (27%) and RPE patients (24%) at 30 days after sus-
pected PE was most likely due to direct mortality ofconfirmed PE during the acute period and the high co-
morbidity of both groups, as shown in other studies
[13].
Mortality of patients with confirmed PE
The International Cooperative Pulmonary Embolism
Registry (ICOPER) and Longitudinal Study of Thrombo-
embolic Etiology (LITE) studies reported short-term
mortality rates for confirmed PE, similar to our findings
for confirmed PE. In the ICOPER study, the main cause
of death was PE, and in the LITE study, mortality was
higher in patients with cancer [34]. Heit et al. [35] re-
ported a slightly higher mortality than our study (28%)
after 30 days, which was likely explained by the inclusion
of PE cases that were identified at autopsy, without clin-
ical suspicion of PE before death. In our study, autopsies
Table 3 Baseline characteristics between complete and lost follow up patients
Complete follow up Lost of follow up p
n = 1573 n = 162
Median age, years 68 63 <0.001
Sex-Female, % 41% 39% 0.60
Median stay, days 8 8 0.67
Comorbidities
Diabetes 13.9% 19.3 % 0.07
Hypertension 65.3% 66.3% 0.81
Smoking 11.9% 16.5% 0.09
Heart Failure 16.9% 15.4% 0.62
Coronary heart disease 12.5% 11.2% 0.64
Dyslipidemia 45.6% 48.8% 0.45
Cerebrovascular Accident 5.8% 5.6% 0.60
Active neoplasia 40.9% 24.1% <0.01
Nephrotic syndrome 0.8% 2.9% 0.21
Charlson Score* 2 1 <0.001
Immobilization within 4 weeks 37% 24.8% 0.04
Median Body Mass Index, kg/m2 27 27 0.04
* p < 0.05. Categorical variables were compared with the chi2 test and continuous variables with the Mann Whitney U test.
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included. Anderson et al. [36] reported a lower mortal-
ity than our study (12%) in confirmed PE, but they only
included patients who died during hospitalization.
Flinterman et al. [24] reported higher 5-year mortality
rates in patients with VTE than in controls. However, this
finding can be explained because the controls did not
present with suspected PE, but were relatives of patients
with VTE or were patients matched for age and sex. In
addition, these controls were younger with a lower preva-
lence of cancer, CHF, and COPD compared with VTE pa-
tients. The study by Flinterman et al. [24] has two features
that are similar to our study: the most frequent causes of
death (cancer, CHF, and PE), and death, which was more
frequent in cancer patients than in the other categories of
risk factors.
We detected a non-significant trend of early death in
patients with confirmed PE, which could be explained
by acute hemodynamic failure at onset and early recur-
rence of fatal PE or fatal bleeding related to anticoagu-
lant therapy. Long-term mortality after PE is probablyTable 4 Survival by category of risk factor
Survival Active cancer N = 688 Provoked N = 85
Confirmed PE (201) Ruled out PE (487) Confirmed PE (2
S (95% CI) S (95% CI) S (95% CI)
1 Year 0.32 (0.24-0.39) 0.32 (0.27-0.36) 0.61 (0.54-0.67)
2 Years 0.26 (0.18-0.33) 0.24 (0.19-0.28) 0.53 (0.45-0.60)
S, Survival; CI: confidence interval; p < 0.05.affected by comorbidities. Another important finding in
our study was that, regardless of the category of VTE
risk factor, patients had a similar risk of death, irrespect-
ive of whether the diagnosis of PE was confirmed or
ruled out. Additionally, this risk was maintained in the
long term follow-up. This could be potentially explained
by the high burden of comorbidities, mainly cancer and
sepsis.
Mortality of RPE patients
Unlike patients with confirmed PE, information on clin-
ical features, evolution, and mortality in patients with
RPE is scarce. van Beek et al. [37], Akram et al. [13], and
Bertoletti et al. [38] reported a lower mortality rate of
PE than in the current study, but the main causes of
death were similar (neoplasm and CHF). The higher rate
of mortality in our study could have been due to base-
line characteristics (older age and comorbidities, particu-
larly cancer) and the follow-up time [38].
Roy et al. [18] reported a similar rate of prevalence of
PE to our study. For those patients who died, fatal PE4 Unprovoked N = 194
53) Ruled out PE (601) Confirmed PE (50) Ruled out PE (144)
S (95% CI) S (95% CI) S (95% CI)
0.69 (0.64-0.75) 0.57 (0.42-0.71) 0.59 (0.50-0.67)
0.57 (0.53-0.60) 0.51 (0.34-0.67) 0.49 (0.49-0.59)
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cancer, CHF, and respiratory disorders were the main
causes of death in RPE patients [18]. Mortality of PE at
90 days greatly varies, from 1.5% [36] to 21.5% [15].
Mortality during follow-up of patients with PE and RPE
In previous studies [13,17,34-37], as well as the present
study, mortality in PE and RPE patients progressively in-
creased during follow up. The most frequent causes of
death were cancer, CHF, and COPD. The reason for this
finding appears to be due to comorbidities (particularly
cancer and vascular disease) that are present in RPE pa-
tients. While comparing confirmed PE and ruled out PE
there was higher mortality in oncologic patients, followed
by those in the unprovoked and provoked group.
Complications during follow-up
VTE and anticoagulation are two of the main independent
risk factors for recurrence of VTE and bleeding. In our co-
hort, new events of VTE and major bleeding were much
higher in patients with confirmed PE than in RPE patients.
This finding reflects “real clinical practice” because pa-
tients were not selected owing to the observational nature
of the study, and a systematic search of asymptomatic
VTE events was not performed. However, the high fre-
quency of bleeding that was detected in RPE patients may
be explained by the presence of multiple risk factors for
bleeding (cancer and chemotherapy), which determined
their initial inclusion in the suspected PE cohort.
We found no increase in the diagnosis of new cancer
cases in patients with confirmed PE, either in the entire
cohort, or in the unprovoked subgroup, which is consist-
ent with previous reports [39,40]. This association has
been particularly described for selected patients with re-
current unprovoked PE, anemia, and bilateral DVT
[39,41,42]. One explanation for our finding may be the
real lack of an association between PE and new cancer.
However, the number of unprovoked patients may have
been insufficient to detect this association.
Limitations of our study
Physicians from our hospital follow the European Society
of Cardiology Guidelines in the diagnostic evaluation of
suspected PE. However, because we performed an obser-
vational study, we were not able to report the chrono-
logical diagnostic test algorithm that was used by each
physician. Our study was conducted in a single center
with a high prevalence of cancer. Our cohort had a preva-
lence of cancer of 40%, while Maestre et al. [43] reported
25% and Bertoletti reported 7% [38]. Therefore, these re-
sults should only be extrapolated to centers with similar
patients. Notably, the extent of neoplasm screening in sus-
pected PE is still poorly standardized in the literature and
depends on the treating physician.Strengths of our study
The main strength of this study was the design of a pro-
spective cohort with a standardized follow-up of all sus-
pected PE incident cases that were generated in real time.
The cases were prospectively collected for the IRTD in a
standardized data collection form and follow-up ensured
high quality of data by minimizing the loss of events. As
an observational study, our study reflected the current
medical practice for patients with suspected PE at a teach-
ing tertiary care hospital. Finally, to the best of our know-
ledge, no other studies have included such a large
numbers of patients with suspected PE or such prolonged
follow-up times.
Conclusion
This study investigated the epidemiological and clinical
characteristics, and short-term and long-term prognoses
of patients with suspected PE. Overall mortality was simi-
lar between patients with confirmed PE and RPE patients,
probably because of the more frequent or more severe co-
morbidities in RPE patients. These findings are relevant
for understanding the prognosis of patients with suspected
PE in everyday medical practice and could help physicians
at the relevant decision-making time.
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